Detalhe da pesquisa
1.
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
Rheumatology (Oxford)
; 63(1): 41-49, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097894
2.
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study.
Clin Exp Rheumatol
; 41(3): 589-596, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35916290
3.
Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.
Rheumatology (Oxford)
; 61(5): 1867-1876, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34528079
4.
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Br J Dermatol
; 187(3): 438-441, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257363
5.
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Clin Exp Rheumatol
; 40(5): 952-959, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34494957
6.
Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.
Clin Exp Rheumatol
; 39(5): 931-937, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33253089
7.
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
Ann Rheum Dis
; 75(10): 1763-9, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590174
8.
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Ann Rheum Dis
; 72(8): 1287-94, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915624
9.
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
RMD Open
; 9(2)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094983
10.
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.
RMD Open
; 9(4)2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37945285
11.
Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
Semin Arthritis Rheum
; 63: 152259, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37660536
12.
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Rheumatol Ther
; 8(1): 273-288, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33351179
13.
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Semin Arthritis Rheum
; 50(4): 709-718, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32521325
14.
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Arthritis Res Ther
; 21(1): 266, 2019 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31801620
15.
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
Arthritis Care Res (Hoboken)
; 70(10): 1529-1535, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29409133
16.
Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study.
RMD Open
; 2(1): e000237, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175297
17.
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Arthritis Res Ther
; 17: 157, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26063454